Cipla challenges HC order against manufacturing generic drughttps://indianexpress.com/article/business/business-others/cipla-challenges-hc-order-against-manufacturing-generic-drug/

Cipla challenges HC order against manufacturing generic drug

Cipla had last year started manufacturing and selling a generic drug using the Indacaterol maleate salt.

Indian Pharma company Cipla on Monday challenged the single bench order of the High court restraining it from manufacturing or selling respiratory drug Indacaterol, before the division bench of the Delhi High court.

On Friday, in a 143 page order, the court of Justice Manmohan Singh had restrained Cipla from manufacturing the drug, which is used to treat chronic obstructive pulmonary disease (COPD), on a plea by Swiss pharma giant Novartis which had claimed that Cipla was violating its patent.

Cipla had last year started manufacturing and selling a generic drug using the Indacaterol maleate salt created by Novartis, under the trademark name Unibrez, which was later changed to Indaflo.

Novartis had approached the High Court last year to permanently restrain Cipla from manufacturing and selling the medicine, as the patent for Indacaterol salt is held by Novartis.